In the panel, we included SFRP1, SFRP2, RUNX3, CBLN4, INA, MGMT, and RASSF1A. The choice of genes was determined based on the established or potential role of promoter methylation of these genes in glioma detection and patients' management. This evidence concerns the gene SFRP2 and central nervous system cancer.